# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 24, "J Diabetes Complications", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasJournal> \"J Diabetes Complications\"."
1, PublicationYear, 27, 31, "2014", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasPublicationYear> \"2014\"."
27, Title, 136, 375, "Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) .", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasTitle> \"Beneficial effects of once - daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin ( GetGoal - S ) .\"."
2, Frequency, 158, 170, "once - daily", "", 
75272, Lixisenatide, 171, 183, "lixisenatide", "", 
16, Hypoglycemia, 258, 270, "hypoglycemia", "", 
125, Precondition, 274, 357, "type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin", "", 
17, Type2Diabetes, 274, 289, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
20, Sulfonylureas, 319, 331, "sulfonylurea", "", 
24, Metformin, 348, 357, "metformin", "", 
28, Author, 376, 388, "Rosenstock J", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasAuthor> \"Rosenstock J\"."
29, Author, 397, 407, "Hanefeld M", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasAuthor> \"Hanefeld M\"."
30, Author, 416, 426, "Shamanna P", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasAuthor> \"Shamanna P\"."
31, Author, 435, 441, "Min KW", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasAuthor> \"Min KW\"."
32, Author, 450, 456, "Boka G", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasAuthor> \"Boka G\"."
33, Author, 465, 474, "Miossec P", "", 
34, Author, 483, 489, "Zhou T", "", 
35, Author, 498, 517, "Muehlen - Bartmer I", "", 
36, Author, 526, 535, "Ratner RE", "", 
37, USA, 640, 643, "USA", "", 
38, Germany, 771, 778, "Germany", "", 
39, India, 827, 832, "India", "", 
40, SouthKorea, 874, 891, "Republic of Korea", "", 
141, SouthKorea, 886, 891, "Korea", "", 
41, France, 934, 940, "France", "", 
42, France, 972, 978, "France", "", 
43, USA, 1015, 1018, "USA", "", 
45, Germany, 1054, 1061, "Germany", "", 
44, USA, 1165, 1168, "USA", "", 
52, ObjectiveDescription, 1178, 1358, "To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasObjectiveDescription> \"To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .\"."
75287, Lixisenatide, 1211, 1223, "lixisenatide", "", 
15, Frequency, 1224, 1236, "once - daily", "", 
46, Placebo, 1244, 1251, "placebo", "", 
51, Precondition, 1255, 1356, "type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin", "", "<http://ctro/data#Population_56687> <http://ctro/data#hasPrecondition> \"type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin\"."
18, Type2Diabetes, 1255, 1279, "type 2 diabetes mellitus", "", 
19, Type2Diabetes, 1282, 1286, "T2DM", "", 
152, Precondition, 1298, 1356, "inadequately controlled on sulfonylurea ( SU ) ± metformin", "", 
21, Sulfonylureas, 1325, 1337, "sulfonylurea", "", 
22, Sulfonylureas, 1340, 1342, "SU", "", 
25, Metformin, 1347, 1356, "metformin", "", 
53, Randomized, 1377, 1387, "randomized", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasObjectiveDescription> \"To assess efficacy and safety of lixisenatide once - daily versus placebo in type 2 diabetes mellitus ( T2DM ) patients inadequately controlled on sulfonylurea ( SU ) ± metformin .\"."
54, DoubleBlind, 1390, 1404, "double - blind", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
55, Parallel, 1419, 1435, "parallel - group", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
56, Multicenter, 1438, 1449, "multicenter", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
75289, Lixisenatide, 1476, 1488, "lixisenatide", "", "<http://ctro/data#Medication_56725> <http://ctro/data#hasDrug> <http://ctro/data#Lixisenatide>."
57, DoseValue, 1489, 1491, "20", "", "<http://ctro/data#Medication_56725> <http://ctro/data#hasDoseValue> \"20\"."
58, Microgram, 1492, 1495, "μ g", "", "<http://ctro/data#Medication_56725> <http://ctro/data#hasDoseUnit> <http://ctro/data#Microgram>."
3, Frequency, 1496, 1508, "once - daily", "", "<http://ctro/data#Intervention_56713> <http://ctro/data#hasFrequency> \"once - daily\"."
59, Placebo, 1512, 1519, "placebo", "", "<http://ctro/data#Medication_56732> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
60, Duration, 1524, 1532, "24 weeks", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasCTduration> \"24 weeks\"."
23, Sulfonylureas, 1571, 1574, "SUs", "", 
26, Metformin, 1577, 1586, "metformin", "", 
62, HbA1c, 1619, 1624, "HbA1c", "", 
64, TimePoint, 1630, 1638, "baseline", "", 
65, TimePoint, 1642, 1649, "Week 24", "", 
75278, Lixisenatide, 1662, 1674, "Lixisenatide", "", 
63, HbA1c, 1711, 1716, "HbA1c", "", "<http://ctro/data#Endpoint_56773> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
66, TimePoint, 1720, 1727, "Week 24", "", 
67, Placebo, 1735, 1742, "placebo", "", 
176, LeastSquaresMean, 1745, 1752, "LS mean", "", "<http://ctro/data#Endpoint_56773> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
69, Reduction, 1757, 1763, "0 . 85", "", "<http://ctro/data#Outcome_56778> <http://ctro/data#hasChangeValue> \"0 . 85\"."
71, Percentage, 1764, 1765, "%", "", "<http://ctro/data#Endpoint_56773> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
70, Reduction, 1773, 1779, "0 . 10", "", "<http://ctro/data#Outcome_56805> <http://ctro/data#hasChangeValue> \"0 . 10\"."
72, Percentage, 1780, 1781, "%", "", 
73, PvalueDiff, 1784, 1796, "p < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_56832> <http://ctro/data#hasPvalueDiff> \"p < 0 . 0001\"."
74, HbA1c_target, 1826, 1841, "HbA1c < 7 . 0 %", "", "<http://ctro/data#Endpoint_56841> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
181, Percentage, 1840, 1841, "%", "", 
75, PercentageAffected, 1844, 1850, "36 . 4", "", "<http://ctro/data#Outcome_56846> <http://ctro/data#hasPercentageAffected> \"36 . 4\"."
182, Percentage, 1851, 1852, "%", "", 
76, PercentageAffected, 1858, 1864, "13 . 5", "", "<http://ctro/data#Outcome_56873> <http://ctro/data#hasPercentageAffected> \"13 . 5\"."
183, Percentage, 1865, 1866, "%", "", 
77, PvalueDiff, 1869, 1881, "p < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_56900> <http://ctro/data#hasPvalueDiff> \"p < 0 . 0001\"."
75280, Lixisenatide, 1886, 1898, "Lixisenatide", "", 
80, ObservedResult, 1899, 1920, "significantly lowered", "", "<http://ctro/data#Outcome_56919> <http://ctro/data#hasObservedResult> \"significantly lowered\". <http://ctro/data#Outcome_56946> <http://ctro/data#hasObservedResult> \"significantly lowered\"."
78, FastingPlasmaGlucose, 1921, 1924, "FPG", "", "<http://ctro/data#Endpoint_56909> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
79, BodyWeight, 1929, 1940, "body weight", "", "<http://ctro/data#Endpoint_56914> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
47, Placebo, 1948, 1955, "placebo", "", 
75281, Lixisenatide, 1992, 2004, "lixisenatide", "", 
81, PostprandialPlasmaGlucose, 2013, 2025, "2 - hour PPG", "", "<http://ctro/data#Endpoint_56973> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PostprandialPlasmaGlucose>."
48, Placebo, 2033, 2040, "placebo", "", 
196, LeastSquaresMean, 2043, 2050, "LS mean", "", "<http://ctro/data#Endpoint_56973> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
85, Reduction, 2055, 2063, "111 . 48", "", "<http://ctro/data#Outcome_56978> <http://ctro/data#hasChangeValue> \"111 . 48\"."
86, Reduction, 2071, 2077, "3 . 80", "", "<http://ctro/data#Outcome_57005> <http://ctro/data#hasChangeValue> \"3 . 80\"."
98, Mg_per_deciliter, 2078, 2085, "mg / dL", "", "<http://ctro/data#Endpoint_56973> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Mg_per_deciliter>."
87, Reduction, 2090, 2096, "6 . 19", "", 
88, Reduction, 2104, 2110, "0 . 21", "", 
100, Millimoles_per_litre, 2111, 2119, "mmol / L", "", 
102, PvalueDiff, 2124, 2136, "p < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_57032> <http://ctro/data#hasPvalueDiff> \"p < 0 . 0001\"."
83, EndPointDescription, 2143, 2160, "glucose excursion", "", "<http://ctro/data#EndPointDescription_57042> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_57041> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_57042>."
89, Reduction, 2165, 2172, "94 . 11", "", "<http://ctro/data#Outcome_57046> <http://ctro/data#hasChangeValue> \"94 . 11\"."
91, Increment, 2180, 2186, "6 . 24", "", "<http://ctro/data#Outcome_57073> <http://ctro/data#hasChangeValue> \"6 . 24\"."
99, Mg_per_deciliter, 2187, 2194, "mg / dL", "", "<http://ctro/data#Endpoint_57041> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Mg_per_deciliter>."
90, Reduction, 2199, 2205, "5 . 22", "", 
92, Increment, 2213, 2219, "0 . 35", "", 
101, Millimoles_per_litre, 2220, 2228, "mmol / L", "", 
93, ObservedResult, 2239, 2246, "reduced", "", 
94, EndPointDescription, 2247, 2264, "2 - hour glucagon", "", 
97, InsulinDose, 2267, 2274, "insulin", "", 
95, EndPointDescription, 2277, 2287, "proinsulin", "", 
96, EndPointDescription, 2294, 2305, "C - peptide", "", 
84, EndPointDescription, 2326, 2329, "AEs", "", "<http://ctro/data#EndPointDescription_57101> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_57100> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_57101>."
103, PercentageAffected, 2334, 2340, "68 . 3", "", "<http://ctro/data#Outcome_57110> <http://ctro/data#hasPercentageAffected> \"68 . 3\"."
75283, Lixisenatide, 2347, 2359, "lixisenatide", "", 
104, PercentageAffected, 2364, 2370, "61 . 1", "", "<http://ctro/data#Outcome_57137> <http://ctro/data#hasPercentageAffected> \"61 . 1\"."
49, Placebo, 2377, 2384, "placebo", "", 
107, EndPointDescription, 2395, 2399, "SAEs", "", "<http://ctro/data#EndPointDescription_57106> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_57105> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_57106>."
105, PercentageAffected, 2402, 2407, "3 . 5", "", "<http://ctro/data#Outcome_57164> <http://ctro/data#hasPercentageAffected> \"3 . 5\"."
106, PercentageAffected, 2417, 2422, "5 . 6", "", "<http://ctro/data#Outcome_57191> <http://ctro/data#hasPercentageAffected> \"5 . 6\"."
75284, Lixisenatide, 2442, 2454, "Lixisenatide", "", 
108, SymptomaticHypoglycemia, 2486, 2510, "symptomatic hypoglycemia", "", "<http://ctro/data#Endpoint_57218> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
50, Placebo, 2518, 2525, "placebo", "", 
109, PercentageAffected, 2528, 2534, "15 . 3", "", "<http://ctro/data#Outcome_57228> <http://ctro/data#hasPercentageAffected> \"15 . 3\"."
110, PercentageAffected, 2542, 2548, "12 . 3", "", "<http://ctro/data#Outcome_57255> <http://ctro/data#hasPercentageAffected> \"12 . 3\"."
232, NumberAffected, 2570, 2591, "one severe episode of", "", "<http://ctro/data#Outcome_57282> <http://ctro/data#hasNumberAffected> \"one severe episode of\"."
230, SevereHypoglycemia, 2574, 2580, "severe", "", "<http://ctro/data#Endpoint_57223> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SevereHypoglycemia>."
230, SevereHypoglycemia, 2592, 2604, "hypoglycemia", "", "<http://ctro/data#Endpoint_57223> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SevereHypoglycemia>."
75285, Lixisenatide, 2623, 2635, "lixisenatide", "", 
117, ConclusionComment, 2652, 2867, "Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks .", "", "<http://ctro/data#ClinicalTrial_56671> <http://ctro/data#hasConclusionComment> \"Once - daily lixisenatide significantly improved glycemic control , with a pronounced postprandial effect , without significant increase in symptomatic / severe hypoglycemia risk and with weight loss over 24 weeks .\"."
4, Frequency, 2652, 2664, "Once - daily", "", 
75292, Lixisenatide, 2665, 2677, "lixisenatide", "", 
114, SymptomaticHypoglycemia, 2792, 2803, "symptomatic", "", 
115, SevereHypoglycemia, 2806, 2825, "severe hypoglycemia", "", 
114, SymptomaticHypoglycemia, 2813, 2825, "hypoglycemia", "", 
237, WeightReduction, 2840, 2851, "weight loss", "", 
61, Duration, 2857, 2865, "24 weeks", "", 
118, PMID, 3005, 3013, "24650952", "", "<http://ctro/data#Publication_56664> <http://ctro/data#hasPMID> \"24650952\"."
